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http://dx.doi.org/10.1016/j.stemcr.2017.03.012SUMMARYLarge-scale collections of induced pluripotent stem cells (iPSCs) could serve as powerful model systems for examining how genetic
variation affects biology and disease. Here we describe the iPSCORE resource: a collection of systematically derived and characterized
iPSC lines from 222 ethnically diverse individuals that allows for both familial and association-based genetic studies. iPSCORE lines
are pluripotentwith high genomic integrity (no or low numbers of somatic copy-number variants) as determined using high-throughput
RNA-sequencing and genotyping arrays, respectively. Using iPSCs from a family of individuals, we show that iPSC-derived cardiomyo-
cytes demonstrate gene expression patterns that cluster by genetic background, and can be used to examine variants associated with
physiological and disease phenotypes. The iPSCORE collection contains representative individuals for risk and non-risk alleles
for 95% of SNPs associated with human phenotypes through genome-wide association studies. Our study demonstrates the utility of
iPSCORE for examining how genetic variants influence molecular and physiological traits in iPSCs and derived cell lines.INTRODUCTION
Due to their ability to differentiate into a variety of cell
types, induced pluripotent stem cells (iPSCs) are a poten-
tially powerful model system to study mechanisms under-
lying non-coding genetic variants associated with human
traits, many of which lie in cell-type-specific regulatory re-
gions (Maurano et al., 2012). However, because non-coding
regulatory variants can have relatively small effect sizes,
hundreds of lines from diverse individuals may be needed
to measure genetic associations as opposed to the tens of
different lines typically used to study disease-associated
coding variants with strong effects (Avior et al., 2016). To
enable the study of genetic variants associated with com-
plex diseases and cell-type-specific molecular phenotypes,1086 Stem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017 j
This is an open access article under the CC BY license (http://creativecommowe and others are establishing large systematically gener-
ated collections of iPSCs toward the goal of generating
large genomic datasets that will be openly available
to researchers (Avior et al., 2016; Kilpinen et al., 2016;
McKernan and Watt, 2013; Streeter et al., 2017). Ongoing
collections, including large disease-focused iPSC reposi-
tories (www.cirm.ca.gov), however, are currently limited
in sample diversity and in related individuals (e.g., pedi-
grees or twins), which would allow for the interrogation
of population-associated genetic variation, rare variation,
and family-based genetic study designs. Thus, the genera-
tion of a resource consisting of hundreds of systematically
derived iPSCs with available genomic data including
SNP arrays, RNA sequencing (RNA-seq), and whole-
genome sequencing, and that includes a variety of familialns.org/licenses/by/4.0/).
architectures and individuals ofmultiple ethnicities, would
further enable a wide variety of study designs to interrogate
the genetic basis of phenotype and disease.
There are a number of potential challenges to using iPSC
and iPSC-derived cells to model human phenotype and
disease. Somatic heterogeneity in iPSC lines that can occur
during isolation and culture may interfere with examining
genetic variants with subtle effects (Fusaki et al., 2009;
International Stem Cell et al., 2011; Nazor et al., 2012).
This heterogeneity can include copy-number alterations,
which have been reported as occurring in recurrently
altered regions in existing collections of pluripotent stem
cells (both embryonic stem cells [ESCs] and iPSCs) (Interna-
tional Stem Cell et al., 2011; Laurent et al., 2011; Taapken
et al., 2011). However, because many of these lines were
not systematically generated andmay have undergone pro-
longed passaging in culture, it is unclear how prevalent
these hotspots are in limited passaged lines and/or if other
hotspots could be uncovered as additional iPSC are exam-
ined. In addition, it is not yet knownwhether iPSC-derived
cell types (cardiomyocytes, neurons, adipocytes) will be
useful for functionally examining genetic variants. We
and others have recently shown that genetic differences be-
tween individuals are associatedwith a variety ofmolecular
phenotypes in iPSCs, including the transcriptome and
epigenome (Burrows et al., 2016; DeBoever et al., 2017;
Panopoulos et al., 2017; Rouhani et al., 2014; Thomas
et al., 2015), but it is still unclear whether genetic
background is associated with molecular phenotypes in
iPSC-derived cells.
Here, we describe the iPSCORE (iPSC Collection for
Omic Research) resource, a systematically derived and
characterized reference panel of iPSC lines. Participants
were recruited to include families, twins, and individuals
of diverse ethnicity to enable genetic studies investi-
gating the segregation of traits. While the majority of
the participants were generally healthy, 39 individuals
with heart diseases were included to allow for investiga-
tions into heart disease using derived cell types. iPSCs
were systematically reprogrammed from fibroblasts
and analyzed for pluripotency and the presence and
recurrence of somatic copy-number variants (CNVs). We
differentiated a subset of iPSCs to cardiomyocytes and
examined how the donor’s genetic background is associ-
ated with gene expression variation in derived cell lines.
Finally, we examined and annotated how individuals in
the iPSCORE resource carry SNPs associated with diverse
genome-wide association studies (GWAS) phenotypes.
The iPSCORE resource provides a powerful tool to
examine how genetic variants influence molecular and
physiological traits across a variety of derived cell types,
as well as to functionally interrogate variants underlying
a variety of GWAS phenotypes.RESULTS
Recruitment and Characterization of Individuals in
the iPSCORE Resource
We recruited individuals and recorded sex, age,medical his-
tory, ethnicity, and relatedness to others in the collection
through a questionnaire at enrollment (Figure 1A). Here-
after, we describe the 222 individuals for which we success-
fully obtained at least one iPSC line (Table S1). There were
124 females ranging in age from 10 to 88 (median age 48),
and 98 males ranging in age from 9 to 82 years of age (me-
dian age 49) (Figure 1B). The resource includes 143 partici-
pants who are members of a family and genetically related
to at least one other individual (Figures 1C and S1). In total,
there are 41 families that contain between 2 and 14 mem-
bers, which include seven monozygotic twin pairs and two
dizygotic twin pairs (example pedigrees in Figure 1D; see
Figure S1 for all pedigrees). Due to the fact that some of
the individuals in the 41 families are only related by mar-
riage, there are a total of 136 genetically unrelated individ-
uals in the collection. While most participants in the
collection do not have heart disease, there were 25 individ-
uals with arrhythmia (some with multiple types), 13 with
cardiomyopathy, and one with structural cardiac malfor-
mations (Figure 1E and Table S1A). Using whole-genome
sequence data generated from the blood of cardiac dis-
ease probands and their families (DeBoever et al., 2017),
we examined genetic variation at candidate disease genes
and identified four potentially disease-associated variants
affecting two families and two singletons (Table S1B). Over-
all, the iPSCORE resource contains both complex family
structures and unrelated individuals across a large spec-
trum of ages and multiple ethnicities predominantly
from healthy donors, but also includes a subset (18%)
of individuals that have a diagnosed cardiac disease.
Germline DNA isolated from blood (or in 16 cases from
fibroblasts) from each participant was hybridized to the
HumanCoreExome BeadChip, and we used the derived
genotypes to confirm reported familial relationships,
ancestry, and sex. We estimated the proportion of the
genome identical-by-descent between each pair of germ-
line samples and observed genetic similarity that was
consistent with reported familial relationships, with no
cryptically related individuals (Figure 1F). Ethnicities were
recorded as free response by the participants (or in aminor-
ity of cases, the physician) and categorized into the
following ‘‘recorded ethnic groups’’ (number of individuals
given): African American (4), Hispanic (15), Asian (30), Eu-
ropean (147), Multiple ethnicities reported (18), Indian (6),
and Middle Eastern (2). We estimated genetic ancestry by
comparing the genetic similarity of the participants to
the 1,000 Genomes Project (1KGP) and observed 100%
concordance with the reported ethnicity and the mostStem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017 1087
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Figure 1. Description of the iPSCORE Cohort
(A) Pipeline for the systematic generation and characterization of 222 iPSC lines. Individuals filled out a questionnaire detailing their
medical history, family relationships to other subjects in the cohort, gender, and ancestry. Fibroblasts from skin biopsy were re-
programmed to integration-free iPSC using Sendai virus and frozen at passage 12. Genomic DNA isolated from the iPSC and the subject-
matched blood samples were hybridized to the HumanCoreExome array. The resulting data were then used to confirm reported family
structure, reported ancestry, and iPSC sample identity (match with blood sample), and to perform CNV analysis (iPSC characterization) and
determine status of known disease risk alleles.
(B) Age distributions of males and females.
(C) Pie chart showing how many individuals are singletons or in a family size of 2, 3, 4, and 5 or more.
(D) Pedigrees of two representative families; numbered individuals indicate presence in the study. Family 3 is a two-generation family with
identical twins (nine subjects), andFamily 12has amember diagnosedwith ventricular tachycardia and congenital heart block (four subjects).
(E) Number of individuals with cardiac disease, grouped by disease type. Some individuals are affected by multiple types of arrhythmia.
(F) Boxplot showing the observed proportion of the genome identical by descent (pIBD) as a function of the reported family relationship.
The box hinges indicate the 25th and 75th quantiles and the whiskers extend to 1.5 times the interquartile range. A red ‘‘X’’ indicates the
expected mean pIBD given the number of generations that separate the individuals.
(G) An x-y plot showing the first versus second components of a principal component analysis using genotype data from a subset of SNPs
present on the array mapped onto a principal component analysis from the 1,000 Genomes Project (1KG) super populations (SP) (small
faded circles). Individuals from the iPSCORE cohort are mapped onto these components with their recorded ethnicity grouping shown by a
colored X.
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similar 1KGP super population using linear discriminant
analysis (Figure 1G and Table S1A). However, some hetero-
geneity was observed in clustering of the first principal
components, consistent with some level of unreported
admixture. Finally, sex was determined from genotype
data and no discrepancies were identified. These results
suggest that the samples analyzed are consistent with re-
ported phenotypes and familial relationships.
Generation, Sample Identity Verification, and
Pluripotency Testing of iPSC Lines
Skin biopsies collected at enrollment were immediately
used to derive fibroblasts for generating iPSCs, while the
blood was stored for later DNA extraction (Figure 1A). We
used a non-integrative reprogramming method (Sendai vi-
rus) to generate the iPSCs and derivedmultiple clones from
each individual (on average three clones), with aminimum
of two clones frozen at passage 3 (P3) and at least one clone
cultured to later passage (typically P12). We attempted to
reprogram fibroblasts from 240 of the recruited partici-
pants and obtained iPSCs for 224 individuals, of which
222 passed sample identity quality control (see below).
To confirm sample identity of the iPSC, we hybridized
DNA isolated from the iPSC samples (typically at P12) to
HumanCoreExome BeadChips and compared it with the
genotype data from the matched germline sample. Sample
identity was considered confirmed if the iPSC line geneti-
cally matched the donor germline sample across 90,099
SNPs. We identified two iPSC lines that did not genetically
match the blood sample: for one, we suspect that the blood
was mislabeled at time of collection, and for the other, that
the iPSC was exchanged with another unknown cell line.
In both cases, the anomalous sample did not match with
any other sample in the study, and both germline/iPSC
pairs were excluded. Overall, 222 of 224 (99.1%) iPSC lines
passed sample identity quality control and were included
in the study.
To evaluate iPSC pluripotency, we conducted flow cy-
tometry and analyzed gene expression using expressionFigure 2. Analysis of iPSC Transcriptome Data to Assess Pluripote
(A) Heatmap and hierarchical clustering showing normalized expres
pluripotency (green) (Burridge et al., 2012; Dubois et al., 2011; Vida
et al., 2015) in 213 iPSCORE iPSC lines and 73 cell lines (21 iPSC, 35
2015). Samples are color coded to show whether they are derived from
the basis of tissue type (red for hESC, green for iPSC, and blue for fibro
expression of pluripotency genes than fibroblasts, which have low
mesoderm markers than iPSC lines and hESC lines.
(B) PluriTest-RNAseq-based analysis of 213 iPSCORE lines (green) wit
density map indicating the location of pluripotent (red) and non-plu
novelty score, which indicates how much the test iPSC deviates from
more somatic characteristics and therefore lower pluripotency. The y
that enables a probability-based choice between pluripotent and non
1090 Stem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017arrays and RNA-seq data. We examined a subset of the
lines (50 samples) by flow cytometry, all of which
showed >95% positive staining for the pluripotency
markers Tra-1-81 and SSEA-4 (Figure S2). For 213 iPSCs
with RNA-seq (DeBoever et al., 2017), we compared the
expression levels of nine pluripotency (Burridge et al.,
2012; Dubois et al., 2011; Vidarsson et al., 2010) and 25
mesoderm markers (Tsankov et al., 2015) to publicly
available RNA-seq data from human ESCs (hESCs),
iPSCs, and fibroblasts (Choi et al., 2015) (Figure 2A).
The iPSCs were comparable with these previously estab-
lished pluripotent stem cell lines, showing low expression
of mesoderm markers and high expression of pluripo-
tency markers (Figure 2A). To further examine iPSC plu-
ripotency, we analyzed the RNA-seq expression data for
the 213 lines using PluriTest-RNAseq, a recently modified
version of PluriTest (Muller et al., 2011) that has been
adapted for RNA-seq (see Supplemental Experimental Pro-
cedures; unpublished data by B.M.S., R.W., F.J.M., and
J.F.L.) as opposed to gene expression arrays. We observed
strong clustering of the iPSCs in the upper left quadrant
with 206 of the lines passing the test’s criteria (>20
Pluripotency Score, indicating high expression levels of
pluripotency-associated gene signatures; <1.67 Novelty,
indicating a low probability of epigenetic or genetic ab-
normalities) (Table S2 and Figure 2B). Of the seven out-
liers, four have normal karyotypes and three have CNVs
that cumulatively account for less than 500 kb in total
length per line (see below and Table S3), suggesting that
the variation in score is not due to genetic abnormalities.
As part of an ongoing project whereby we are differenti-
ating these iPSC lines into cardiomyocytes (see below),
we attempted to differentiate four of the outlying samples
and successfully differentiated three, which is similar to
the overall 78% success rate (147 of 188 attempted)
for first cardiac differentiation attempts, indicating that
these outliers show differentiation rates similar to passing
lines (data not shown). Thus, these results support that
the iPSCORE lines are pluripotent.ncy
sion levels (Z scores derived from VST expression levels) of nine
rsson et al., 2010) and 25 mesoderm marker genes (pink) (Tsankov
hESC, and 17 fibroblast) obtained from GEO: GSE73211 (Choi et al.,
iPSCORE (dark brown) or from GEO: GSE73211 (light brown), and on
blast). The heatmap shows that iPSCs and hESCs have higher overall
expression of pluripotency genes, but higher expression of most
h RNA-seq data. The red and blue background encodes an empirical
ripotent (blue) cells in the reference dataset. The x axis represents
a normal pluripotent line, with higher values being associated with
axis represents the pluripotency score, a logistic regression model
-pluripotent classes (Muller et al., 2011).
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Characterization of Somatic Copy-Number Variants
Previous studies have shown that iPSC lines can contain
somatic CNVs that were either present in the donor sample
or arose during/after the reprogramming process (Abyzov
et al., 2012; Hussein et al., 2011, 2013; Young et al.,
2012). To examine the genomic integrity of the iPSC lines,
we compared the intensity levels and B-allele frequencies of
the HumanCoreExome arrays between the matched germ-
line and iPSC DNA samples.We used a visual approach and
a paired analysis in Nexus CN, a method that requires iPSC
variants to be different from germline, and thus excludes
inherited CNVs (see Supplemental Experimental Proced-
ures). We identified 199 regions from 121 cell lines that
met our criteria for CNVs with high confidence (listed in
Table S3A and Figure S3). Notably, 101 of the 222 iPSC lines
(as scored by the criteria described here) have no significant
CNVs when compared back with their corresponding
germline sample. This is followed by a distribution of iPSCs
having between one CNV (69 lines) and six CNVs (1 line)
(Figure 3A). We observed one trisomy (chromosome X),
one event involving amplification of an entire chromo-
somal arm (chromosome Xp), and 197 subchromosomal
alterations including 151 deletions, 43 amplifications,
one loss of heterozygosity, and two allelic imbalances
(likely caused by subclonal populations) (Table S3A). Size
ranges for subchromosomal alterations ranged from 0.1
Mb to 48.1 Mb (average 1.3 Mb; median 285 kb). For
each of the 121 iPSC lines containing one or more CNV,
we calculated the cumulative amount (in bp) of CNVs
(average 3.8 Mb; median 473 kb) (Figure 3B). A small num-
ber of lines carried a disproportionate burden, with 19 lines
having more than 2 Mb of CNVs and 33 having more than
1 Mb. Of note, these subchromosomal alterations are
almost exclusively outside the detection limits ofG-banded
karyotyping, which typically cannot detect genomic ab-
normalities <5Mb (Manning andHudgins, 2007;ManningFigure 3. Characteristics of the Copy-Number Variants in the 222
(A) Histogram showing the number of iPSC cell lines with (N) detected
aberrations detected.
(B) Histogram showing the cumulative size of CNVs (in megabase pai
(C) Histogram showing the number of alterations in each genomic l
indicated. Gray lines separate chromosomes.
(D–H) Genomic intervals harboring significantly clustered CNVs. The
vertical lines delineate the regions significantly enriched, but additio
expressed genes are color coded. RNA-seq data of the 213 iPSC lines w
not expressed (gray) if fewer than 10 iPSC had an expression level of
considered as having low expression (light blue); while genes with a
underneath the genes show 15 chromatin states in one ESC line (ESC.4
(http://egg2.wustl.edu/roadmap/ [Ernst and Kellis, 2012; Roadmap E
harbor deletions (red rectangles) at chr2q23.3, of which five fall in the
harbors a loss at chr4q23. (F) Three samples harbor deletions at chr1
seven fall in the associated region. (H) Two samples harbor deletions
1092 Stem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017et al., 2010), and therefore these lines would be considered
‘‘normal’’ using a standard method of iPSC characteriza-
tion. Thus, a majority (90%) of iPSCORE lines showed
no detectable CNVs (101/222, or 45%) or carried CNVs
less than 2 Mb (102/222, or 46%).
To investigate whether the somatic CNVs occurred prior
to or during/following initial reprogramming (we cannot
distinguish between mutations that occurred before or af-
ter the cell became an iPSC colony) versus during subse-
quent iPSC passaging in culture, we selected 17 iPSC lines
containing a total of 33 CNVs at P12–P15, and compared
their genotypes with a sample of the same line taken at
an earlier passage (P3). Only three of the CNVs (9%) were
not present at the earlier P3 version of the iPSC line, while
30 (91%) were present (Table S3B). For six of the iPSC lines
(containing a total of 11 CNVs), we examined two addi-
tional clones at P3, and for one of the lines (containing
two CNVs), we examined one additional clone at P3 (Table
S3B). Only one of the 13 CNVs examined was present in
another clone derived from the same fibroblast culture.
These results are in agreement with previous studies that
have found most somatic variants (single-nucleotide vari-
ants [SNVs] and CNVs) are present at low frequency in
the cells of origin and are already present in early passages
(Abyzov et al., 2012; Gore et al., 2011; Hussein et al., 2011;
Laurent et al., 2011; Mayshar et al., 2010; Ruiz et al., 2013;
Young et al., 2012). Our data suggest that systematically
generated iPSC lines do not tend to acquire passage-
associated CNVs (i.e., when passaged 12–15 times) and
that most CNVs are detectable at early stages following
iPSC derivation.
Recurrently Altered Chromosomal Regions
To identify genomic regions thatmay be recurrently altered
in iPSCs, we plotted the distribution of the 199 CNVs and
then looked for 100-kb-long intervals containing moreiPSC Cell Lines
CNV aberrations (x axis); for example, 101 of the iPSC lines have zero
rs) per iPSC cell line as a percentage of the cohort (Total = 222).
ocus. The five intervals harboring a significant cluster of CNVs are
relative chromosomal position of each CNV cluster is shown. Red
nal nearby CNVs are also shown. In each panel, expressed and non-
ere used to determine gene expression levels: genes were defined as
transcripts per million (TPM) >2; genes with a mean TPM <4 were
mean TPM >= 4 were considered as expressed (dark blue). The rows
STAR; top row) and five iPSC lines derived from Roadmap ChromHMM
pigenomics et al., 2015]). (D) Nine samples (sample ID indicated)
significantly enriched region. (E) Two samples harbor gains and one
6p13.3. (G) Nine samples harbor deletions at chr20p12.1, of which
at chr 22q12.1.
AB
C
F
G
E
D
(legend on next page)
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CNVs than expected by chance (Figure 3C). We observed
five small regions (ranging from 200 to 400 kb) affecting
21 of 222 (9%) iPSC lines where CNVs occurred signifi-
cantly more often than expected considering a uniform
distribution across each individual chromosome (signifi-
cance testing for aberrant copy number, p < 0.05) (Figures
3D–3H; Tables S3A and S3C). The most prevalent recur-
rent regions occurred on chr2 (chr2q23.3) and chr20
(chr20p12.1), containing an accumulation of five and
seven subchromosomal CNVs (all deletions), respectively.
The region on chr2 (chr2q23.3) lies in a relatively quiescent
interval (not bound by regulatory proteins or modified his-
tones) between two genes: RPRM (Reprimo, TP53 Depen-
dent G2 Arrest Mediator Candidate), a tumor-suppressor
gene involved in the regulation of p53-dependent cell-
cycle arrest (Xu et al., 2012), and thus of potential interest
due to the established importance of the p53 pathway
in reprogramming (Krizhanovsky and Lowe, 2009); and
GALNT13 (Polypeptide N-Acetylgalactosaminyltransferase
13), a gene expressed at low levels in iPSCs that is involved
in the glycosylation of mucins (Hang and Bertozzi, 2005).
The chr4 region (chr4q23) overlaps active enhancers and
an expressed gene in iPSCs: TSPAN5 (tetraspanin 5), a
member of the transmembrane 4 superfamily involved in
the regulation of cell development and growth (Zhou
et al., 2014). Although the gene (RBFOX1: RNA Binding
Protein, Fox-1 Homolog) in the significantly enriched
region on chr16 (16p13.3) is not expressed in iPSCs, the
interval has previously been shown to be recurrently
aberrantly methylated in iPSC lines (Ruiz et al., 2012).
The chr20 region (chr20p12.1) affects a relatively quiescent
interval and a protein-coding gene expressed at low levelsFigure 4. Differentiation of iPSC Lines into Cardiomyocytes and F
(A) Pedigree of the iPSCORE family 2 showing segregation of KCNH2 m
incomplete penetrance. Individuals with filled in circles display long
mutation.
(B) Protocol used for cardiomyocyte differentiation (Lian et al., 2013)
added to cell culture. Arrows at the top indicate the time points at w
sponding to the differentiation stages of pluripotency (day 0 [d0]
committed cardiovascular cells (d9), and cardiomyocytes (d15) (Paig
(C) Heatmap and hierarchical clustering of expression of the 500 gen
course samples. Samples (columns) are color coded based on the time
the subject from whom they were derived (2_2, 2_3, and 2_9). Genes
according to the differentiation stage where they were first expresse
reported Z scores of variance stabilized transformed read counts.
(D–F) Analysis of iPSC-derived cardiomyocytes from individual 2_3. (D
sarcomeric a-actinin (ACTN1) (red), Cx43 (green), or MLC2-a (green) a
cell membranes especially at cardiomyocyte cell-cell junctions. DAPI
measured from one electrode of one well before and after treatment of
boxplot of beat period calculated from the same data.
(G) Real-time qPCR specifically quantifying the transcripts of KCNH2
expression (DCt) in the iPSC-CMs from seven family members. Expres
Error bars represent SDs.
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gene involved in autism (Jones et al., 2014) and in tamox-
ifen resistance in breast cancer (Mohseni et al., 2014). The
chr22 region (chr22q12.1) affects two protein-coding
genes, as well as an antisense RNA, all transcribed in
iPSCs: PITPNB (Phosphatidylinositol Transfer Protein,
Beta), TTC28 (tetratricopeptide repeat domain 28), and
TTC28-AS1 (TTC28 Antisense RNA 1). Although not a
statistically significant enrichment in our study due to
the relatively high number of CNVs in the iPSC lines on
chr20 (resulting in a high background rate for this chromo-
some), we observed three CNVs overlapping the previously
identified chr20q11.2 hotspot region (Laurent et al., 2011)
linked with the pluripotency and cell proliferation-associ-
ated gene DNMT3B (DNA (Cytosine-5-)-Methyltransferase
3 Beta) (Lefort et al., 2008). The fact that the regions signif-
icantly enriched for CNVs in our study show other recur-
rent alterations (aberrantmethylation on chr16) or contain
actively transcribed genes involved in cell growth and
development (chr4, chr22), suggest that these genomic
intervals may have functional effects in iPSCs.
iPSC-Derived Cardiomyocytes Can Be Used to Study
Molecular and Physiological Traits
To demonstrate the utility of the iPSC lines for studying
how genetic variants influence molecular and physiolog-
ical traits in derived cells, we generated iPSC-derived cardi-
omyocytes (iPSC-CMs) from individuals in a three-genera-
tional family that shows segregation of long-QT syndrome
type II (Figure 4A). We differentiated three individuals
(2_2, 2_3, and 2_9) in triplicate and profiled them using
RNA-seq at five different cardiac differentiation stagesunctional Characterization
utation (p.W1001*) underlying dominant long-QT syndrome with
-QT syndrome, while individuals with black dots are carriers of the
. Arrows at the bottom indicate the reagents that were sequentially
hich cells were collected for whole transcriptome analysis, corre-
), mesodermal progenitors (d2), cardiovascular progenitors (d5),
e et al., 2012).
es with highest variance in expression levels among the 45 time-
point at which they were collected (days 0, 2, 5, 9, and 15) and on
(rows) are color coded by the four groups (hierarchical clustering),
d or most highly expressed (Table S4). Gene expression values are
) Confocal images of iPSC-CMs from sample 2_3 immunostained with
t day 34 post differentiation. Cx43 puncta are observed on hiPSC-CM
was used to counterstain nuclei. MEA analysis: (E) field potential
iPSC-CMs from sample 2_3 with isoproterenol (IC50 0.01 mM), and (F)
with the two genotypes (mutated or wild-type), relative to GAPDH
sion values are normalized relative to the average of DCt.
(45 independent samples) (Figure 4B). The five profiled
stages were each subsequent to important chemical stimuli
in the differentiation process that were previously shown
to result in epigenetic changes (Paige et al., 2012): plurip-
otent (day 0 [d0]), mesodermal progenitors (d2), cardiovas-
cular progenitors (d5), committed cardiovascular cells (d9),
and cardiomyocytes (d15). We selected the 500 most varia-
bly expressed autosomal genes, divided them into four
groups using hierarchical clustering, and annotated them
according to the differentiation stage where they were
most highly expressed (89 genes expressed at d0, 26 at
d2, 41 at d5, and 274 at the combined d9–d15) (Figure 4C).
The triplicate samples for each individual at each of the
five stages clustered together (the two sets of triplicates
at d9 and d15 clustered), suggesting that genetic back-
ground correlates with expression differences between
the different iPSC lines and derived cardiomyocytes. We
performed functional enrichment analysis to confirm
that genes in each of the four groups of genes recapitulate
important stages of cardiac development. This analysis
showed that the genes in group d0 were enriched in gene
ontology terms associated with stem cells and processes
involved in the specification of cell identity, group d2
genes were involved in mesoderm development and
gastrulation, and group d5 genes were associated with
embryo and organ development, whereas genes in group
d9–d15 were involved in heart muscle development (Table
S4). These results are in accordance with the cardiac differ-
entiation stages described by Paige et al. (2012). The iPSC-
CMs from sample 2_3 were further interrogated by immu-
nofluorescence for the presence of typical cardiac structural
markers, ACTN1, CX43, and MLC2a, and this confirmed
that cardiomyocyte-like sarcomeres and gap junctions
had developed (Figure 4D). Thus, the iPSCs can be differen-
tiated to cardiomyocytes that show appropriate cardiac
morphological structures as well as gene expression pat-
terns that cluster by genetic background.
iPSC-CMs could potentially be used as a model system
to assess individual response to drugs through in vitro
functional and pharmacological assays. We characterized
cardiomyocytes from 2_3 and three additional cell lines
(2_1, 13_1, and 14_2) using multielectrode array analysis
(MEA), which records extracellular field potentials of
clusters or layers of cells and provides measurement of
cardiac electrophysiology analogous to an electrocardio-
gram recording (Figures 4E and S4). All four cell lines dis-
played cardiomyocyte-like electrophysiological propri-
eties. When we exposed sample 2_3 to isoproterenol, a b1
and b2 adrenoreceptor agonist used for the treatment of
bradycardia and heart block, cardiomyocytes showed a
significantly increased beat rate (Figures 4E and 4F), consis-
tent with previous reports (Mandel et al., 2012; Scott et al.,
2014; Sirenko et al., 2013). Thus, these observations sug-gest that cardiomyocytes derived from this collection
show expected electrophysiological properties in response
to drug stimulus, and therefore may allow for studying
the genetic components underlying drug response differ-
ences between individuals.
The long-QT syndrome that shows segregation in
iPSCORE family 2 (Figure 4A; Table S1A) is caused by the
p.W1001* mutation in KCNH2, which encodes the a sub-
unit of a potassium ion channel essential for the final repo-
larization of the ventricular action potential (Kupershmidt
et al., 2002). It has been proposed that the disease mecha-
nism for thismutation is the reduction of the rapid delayed
rectifier current (IKr) due to degradation of the transcript by
nonsense-mediated mRNA decay (NMD), and consequent
prolongation of the action potential (Gong et al., 2007).
To examine this hypothesis, we generated d15 iPSC-
derived cardiomyocytes from additional family members
(2_1, 2_4, 2_6, and 2_7) and analyzed KCNH2 expression
in all seven individuals by allele-specific qPCR. We found
that in the carriers of the mutation, the transcript from
the mutated allele was reduced by 75% (t test p = 7.4 3
107) with respect to the wild-type allele, consistent with
the proposed NMD hypothesis (Figure 4G). These results
demonstrate that iPSC-derived cell types can be used to
investigate mechanisms underlying the association of
genetic variation with molecular, physiological, and dis-
ease phenotypes.
iPSC Lines Carry Genetic Variants Associated with a
Variety of Traits and Diseases
Given that many of the iPSC lines in the iPSCORE resource
are from healthy donors, they may be useful for examining
common genetic variants associated with non-cardiac phe-
notypes.GWAShave examinedhundreds ofhumanpheno-
types and identified thousands of SNPs associated with one
ormore trait (Cingolani et al., 2012).We identified 2,571 of
these GWAS SNPs present on the HumanCoreExome arrays
that are associated with one or more phenotype and report
the risk allele genotypes from the germline samples of the
222 participants (Figure 1A and Table S5). In addition, we
examined the distribution of risk/risk, risk/non-risk, and
non-risk/non-risk genotypes at these GWAS SNPs and
found that for 95% (2,434/2,571), each of the three geno-
types was represented, the totals for which can be seen in
Figure 5A. These phenotypes include those that are relevant
to cardiovascular disease, diabetes, andneurological health,
such as QT interval, coronary artery disease, fasting glucose
levels, and late-onset Alzheimer’s disease (Figures 5B–5E). It
has been shown that iPSC lines can be differentiated into a
variety of human cell types, including adipocytes (Lian
et al., 2016), cardiomyocytes (Burridge et al., 2014), he-
matopoietic progenitor cells (Ferrell et al., 2015), pancreatic
b cells (Tulpule et al., 2013), and several different neuronalStem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017 1095
QT interval
R/R R/NR
NR/
NR
rs4725982_T AOC1 −KCNH2 33 83 106
rs2968864_C AOC1 −KCNH2 11 59 152
rs2968863_T AOC1 −KCNH2 10 60 152
rs10919071_A ATP1B1 178 41 3
rs17779747_T CALM2P1 −CASC17 17 96 109
rs7188697_A CNOT1 122 79 21
rs2478333_A GNG5P5 −NAP1L4P3 19 82 121
rs2074238_T KCNQ1 2 19 198
rs12576239_T KCNQ1 6 62 154
rs12296050_T KCNQ1 16 96 110
rs2074518_T LIG3 26 113 83
rs8049607_T LITAF −SNN 55 105 62
rs13017846_G LOC101929667 12 43 167
rs12029454_A NOS1AP 11 63 148
rs4657178_T NOS1AP 24 87 111
rs12143842_T OLFML2B −NOS1AP 16 80 124
rs2880058_G OLFML2B −NOS1AP 41 92 89
rs11970286_T RPL29P4 −CEP85L 28 105 89
rs11153730_C RPL29P4 −CEP85L 35 104 83
rs11129795_A SCN5A 7 73 142
rs12053903_C SCN5A 28 103 91
A Coronary artery disease
R/R R/NR
NR/
NR
rs602633_T CELSR2 −PSRC1 8 63 151
rs9982601_T LINC00310 −KCNE2 1 51 170
rs9369640_C PHACTR1 23 96 103
rs17114036_G PPAP2B 185 36 1
rs11556924_T ZC3HC1 97 99 26
Fasting plasma glucose
R/R R/NR
NR/
NR
rs560887_C G6PC2 12 58 152
rs4607517_A GCK −YKT6 4 58 160
rs1387153_T RPS3AP42 −MTNR1B 19 93 110
rs2166706_G RPS3AP42 −MTNR1B 34 118 70
Alzheimers disease (late onset)
R/R R/NR
NR/
NR
rs7561528_A BIN1 −CYP27C1 17 84 121
rs6656401_A CR1 6 67 147
rs6701713_A CR1 12 90 120
rs4676049_A EDAR −SH3RF3−AS1 3 31 188
rs11771145_G EPHA1−AS1 87 106 29
rs2373115_G GAB2 123 86 13
rs11754661_A MTHFD1L 0 31 191
rs2075650_G TOMM40 0 50 172
rs1476679_T ZCWPW1 115 96 11
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Figure 5. Distributions of GWAS SNP Genotypes in the iPSCORE Resource
(A) Stacked barplot showing the number of individuals in the iPSCORE resource that have particular genotypes at 2,571 SNPs that have
been previously associated with one or more phenotypes through GWAS.
(B–E) Counts of individuals that carry the risk/risk (R/R), risk/non-risk (R/NR), and non-risk/non-risk (NR/NR) genotypes for SNPs
implicated in the indicated disease. The color of the box indicates the number of individuals on a color scale shown at the bottom. (B) QT
interval; (C) coronary artery disease; (D) fasting plasma glucose levels; and (E) Alzheimer’s disease (late onset).
See also Table S5.cell types (Sances et al., 2016). Thus, the iPSC lines in
the iPSCORE resource could be used to investigate the
molecular mechanisms underlying the genetic risk for a
wide variety of traits and diseases in the appropriate derived
cell types.DISCUSSION
Current large-scale collections of iPSCs generally have
limited numbers of lines from people of non-European
ancestry or individuals in multigenerational families. The
iPSCORE collection includes 75 lines from people of His-
panic ethnicity, non-European ancestry, or multiple ances-1096 Stem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017tries, which will aid in studies interrogating population-
associated genetic variation or in fine-mapping using
trans-ethnicity mapping. Additionally we include multi-
generational families and monozygotic twins, which will
enable interrogation of rare, family-specific variation,
segregation analysis of molecular and physiological traits,
and estimation of technical and environmental variation
independent of genetic background. The 136 genetically
unrelated individuals in the resource enable the derived
cell lines to be used for genetic association studies that
historically have required unrelated individuals; although
with methods that account for sample structure (Kang
et al., 2010), these studies can incorporate all 222 individ-
uals. These association studies will be further augmented
by the fact that whole-genome sequence data has been
generated from somatic tissue (blood and in some cases fi-
broblasts) of the iPSCORE participants and is part of the
resource (Table S1C). Because risk and non-risk alleles for
the vast majority of GWAS SNPs are represented in the ge-
nomes of the 222 individuals, this resource will allow for
the functional interrogation of these important predomi-
nantly regulatory variants in appropriate iPSC-derived
cell types. Thus, the nature of the individuals who partici-
pated in the iPSCORE resource will allow for diverse
experimental approaches to examine how genetic varia-
tion affects molecular and physiological traits.
To efficiently characterize more than 200 iPSC lines, we
incorporated genomic tools such as theHumanCoreExome
BeadChip to examine genomic integrity, establish sample
identity, and estimate genetic ancestry and familial related-
ness; and RNA-seq to establish pluripotency. Overall,
genomic integrity for these low-passage lines was high
with almost half of the iPSCs in the iPSCORE resource
showing no detectable abnormalities, and 90% showing
less than 2 Mb of cumulative CNV coverage (in bp). It is
important to note that genotype array assays are limited
to the extent that they are unable to detect balanced chro-
mosomal translocations or abnormalities occurring at a
frequency lower than 20% (D’Antonio et al., 2017 [this
issue of Stem Cell Reports]); however, previous studies using
genotype arrays have found higher ratios and frequencies
of abnormalities in iPSCs (International Stem Cell et al.,
2011; Laurent et al., 2011; Taapken et al., 2011) than
we report, suggesting that a systematic approach to iPSC
generation can result in significantly fewer abnormalities.
We also used RNA-seq data to validate the quality of the
iPSCORE lines by comparing them with publicly available
RNA-seq data for stem cells previously shown to be
pluripotent and performed pluripotency estimation using
PluriTest-RNAseq. Thus, the adoption of high-throughput
genomic methods can help reduce costs and enable effec-
tive and relatively rapid characterization of iPSC lines for
genomic integrity and pluripotency.
Although we observed low overall rates of CNVs, we
observed five recurrently altered regions. Three of the
intervals are quiescent, containing few (if any) regulatory
elements and either low or unexpressed genes. However,
one of these intervals (the chr16 interval) is recurrently
aberrantly methylated in iPSC lines (Ruiz et al., 2012),
which suggests that the region has functional significance
in iPSCs. The other two recurrently altered intervals
contain actively transcribed genes involved in cell growth
and development in iPSCs. Further studies are needed to
determine whether these significantly altered intervals
offered a selective advantage in the reprogramming process
or were due to hotspots that recurrently mutate at a low
rate (2%–4%) in iPSCs (or the parental cells). Previousstudies have shown that most somatic variants (both
CNVs and SNVs) observed in iPSCs are already present in
the cell of origin (Abyzov et al., 2012; Cheng et al., 2012;
Gore et al., 2011; Ruiz et al., 2013; Young et al., 2012).
We observed in a small number of lines that the majority
of somatic CNVs observed in later-passage iPSCs (P12)
were already present at earlier passages (P3), supporting
the model that most somatic variants are likely derived
from the parental cell. In total, these data suggest that
while a significant number of our systematically generated
iPSCs examined at relatively early passage (P12) do not har-
bor detectable genomic alterations, some iPSCs showed
recurrently altered genomic intervals that may reveal a
selective advantage during the reprogramming process,
and that many of these may be present in the cell of origin.
In summary, iPSCORE is a high-quality large-scale collec-
tion of iPSCs from222 individuals that is currently publicly
available through the NHLBI-contracted biorepository at
WiCell Research Institute, with phenotype and genomic
data (SNP arrays, RNA-seq, whole-genome sequencing)
being released through public databases. We are currently
using the resource to differentiate the iPSC lines into cardi-
omyocytes with the intention of investigating molecular
(ATAC-seq [assay for transposase-accessible chromatin
with high-throughput sequencing], DNA methylation,
H3K27ac marks) and physiological phenotypes in both
iPSC lines and iPSC-derived cardiomyocytes. As these,
and other genomic (such as whole-genome sequences)
and molecular data for a variety of derived cell types
become available, the resource will become substantially
richer over time, enabling the research community to effi-
ciently address a multitude of questions regarding human
biology and disease.EXPERIMENTAL PROCEDURES
Enrollment of Subjects for the iPSCORE Resource
This resource was established as part of the Next Generation Con-
sortium of the National Heart, Lung and Blood Institute and is
available to researchers through the biorepository at WiCell
Research Institute (www.wicell.org; NHLBI Next Gen Collection).
For-profit organizations can contact the corresponding author
directly to discuss line availability. Healthy individuals were re-
cruited for the resource through both the Twin Sibling Pedigree
cohort (TSP; a population-based twin registry spanning counties
in Southern California) (Pasha et al., 2013) and open enrollment
through the Clinical and Translational Research Institute (CTRI)
at the University of California at San Diego (UCSD). Thirty-nine
patients at UCSD Sulpizio Cardiovascular Center were also
recruited. These collections were approved by the Institutional
Review Boards of the UCSD and The Salk Institute (Project no.
110776ZF). Each of the subjects first consented to the study and
filled out a questionnaire. These datawere transcribed to a database
and subjects were de-identified with a new sample ID (Table S1A).Stem Cell Reports j Vol. 8 j 1086–1100 j April 11, 2017 1097
Family relatedness was also recorded in the questionnaire and con-
verted into pedigree diagrams using family tree drawing software
(Madeline 2.0, University of Michigan) (Figure S1). Ethnicity was
reported as a free-response answer and translated into one of
six recorded ethnicity groupings (African American, European,
Hispanic, Indian, Middle Eastern, Asian) (Table S1A). A seventh
category was used when more than one ethnicity was reported;
that individual was recorded as ‘‘Multiple ethnicities reported.’’
For 12 individuals, the race/ethnicity question was reported
by a treating physician (Table S1A, denoted by an asterisk in
column K). Finally, a blood sample (for germline DNA) was
collected and a skin biopsy was performed to generate fibroblast
stocks for iPSC reprogramming.
ACCESSION NUMBERS
Phenotype, array genotype, RNA-seq expression values, and
whole-genome sequence genotype data are available through
dbGaP: phs000924 and phs001325. The 222 iPSC lines are avail-
able through WiCell Research Institute (www.wicell.org; NHLBI
Next Gen Collection). Note: The informed consent for the individ-
uals in the iPSCORE resource included the allowance for commer-
cial use. However, licensing agreements are still required between
individual commercial entities and DNAVEC (maker of SeV) and
Wicell (iPSC bank).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and five tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
03.012.
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